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Camptothecin (CPT) and derivatives are topoisomerase I poisons currently used as 
anticancer drugs. Their cytotoxicity is maximal for cells in S phase. Using asynchronous and 
S phase-synchronized HeLa cells, we have shown that both the nuclear factor-κB (NF-κB) 
activation and its transcriptional activity, induced by CPT treatment, are enhanced in S phase 
cells. After CPT treatment, NF-κB activation reaches a maximum in 2-3 hours and is still 
detectable after 24 hours. The nature of the complex evolves with time, forming mostly 
p50/p65 after 2 hours to almost exclusively p52 after 24 hours. In HeLa cells, the different 
steps of the induction are readily observable in S phase synchronized cells whereas they were 
difficultly noticeable in a randomly growing cell population. The signal progresses through 
the activation of the IKK complex, the phosphorylation of IκBα, the degradation of 
phosphorylated-IκBα  and -IκBβ. The stable expression of wild-type HA-tagged-IκBα or 
mutated HA-tagged-IκBα (S32,36A) allowed us to confirm essential role of Ser32 and Ser36. 
NF-κB-activating kinase (NIK) could play a role upstream of the IKK complex as the 
transient expression of a kinase inactive mutant NIK(K429,430A) abolishes the activation of 
NF-κB by CPT. A kinase inactive mutant of mitogen-activated protein/ERK kinase kinase 1 
(MEKK1) another kinase susceptible to act upstream of the signalsome does not. Cytotoxicity 
studies, with clonal populations expressing different amounts of wild-type or mutated IκBα, 
revealed that the overexpression of wild-type IκBα in large amount increases the sensitivity of 













Camptothecin (CPT) and derivatives are potent anticancer agents which inhibit DNA-
topoisomerase I. The drug reversibly stabilizes the transient intermediate comprising DNA 
topoisomerase I covalently linked to the broken DNA strand, preventing the religation of the 
nick [1;2]. The CPT-topoI-DNA complexes (also called "cleavable complexes") can later be 
converted into lethal double-strand breaks by the replication machinery of the dividing cells 
[3-5]. Numerous studies have shown that actively dividing cells are more sensitive to CPT 
than non-dividing cells and that S-phase specific apoptosis can be detected in some cell types 
[6;7]. However, the precise way by which the cells attempt to deal with these double-strand 
breaks as well as the exact cell death pathway are yet undetermined. In addition to apoptosis, 
cell cycle arrests in G1, G2 and at internal S phase checkpoints are also observed following 
CPT-treatment [8;9]. Cells with an hypersensitivity to ionizing radiation or with abnormal cell 
cycle checkpoint in response to ionizing radiation, such as cells derived from individual 
suffering from ataxia telangiectasia (AT) or Nijmegen Breakage Syndrome, are more sensitive 
to CPT [10-12]. This enhanced sensitivity indicates the importance of post-DNA lesion 
processes.  
Our laboratory and others reported that CPT activates the transcription factors NF-κB 
[13-15]. NF-κB belongs to a family of transcription factors composed of homo- or hetero-
dimers of Rel proteins (p50, p65 (RelA), p52, RelB, c-Rel) which play an important role in 
the cellular response to stress. It is activated by many different extracellular stimuli among 
which pro-inflammatory cytokines (TNFα, IL1), bacterial lipopolysaccharides, phorbol esters, 
radiations (UV, X-rays), some viral proteins, ds-RNA, oxidative stress… [16-18]. Once 
activated, NF-κB modulates the expression of many genes involved in cellular events so 
diverse as inflammatory responses, cell growth and differentiation control, malignant 
transformation, and apoptosis [16;19-21]. A large body of literature comments on the anti-
apoptotic function of NF-κB, but it is also evident that for some cell types and in some 
situations, NF-κB does not affect the cell faith or exhibits pro-apoptotic functions [21-23].  
Currently, the best known activation pathway for NF-κB, is the cascade of events 
triggered by pro-inflammatory cytokines TNFα and IL1β  [16;17;24]. In non-stimulated cells, 
NF-κB is maintained in the cytoplasm by a family of inhibitory proteins IκB (IκBα, IκBβ, 
IκBε, p100, p105). Upon stimulation by TNFα, IκBα is phosphorylated on two critical serine 
residues (S32 and S36) by the IKK complex, which itself needs to be activated by 
phosphorylation [25;26]. The phosphorylation of both serines 32 and 36 is the key step in 
regulating the multi-ubiquitination of phosphorylated-IκBα (P-IκBα) on two adjacent lysine 
residues (L21 and L22) and its subsequent degradation by the 26S proteasome. Free NF-κB 
then translocates into the nucleus where it binds to its target sequences. Though this system is 
the best studied, it is not the only possible route of activation. Other activation pathways 
independent of the IKK kinase complex were reported i.e. after oxidative stress or UV 
irradiation [18;27;28].  
In this work, we studied the mechanism of activation of NF-κB by CPT. We present 
data indicating that CPT-induced NF-κB activation is mainly restricted to S phase. Although 
the kinetic of induction is different from the one observed with TNFα, the induction involves 
similar intermediates : (i) activation of the IKK complex, (ii) phosphorylation of IκBα on S32 
and S36 and (iii) degradation of the phosphorylated-IκBα and -IκBβ, (iv) participation of the 
26S proteasome. The involvement of two members of the MAP kinase family, NF-κB 
activating kinase (NIK) and the mitogen-activated protein kinase/ERK kinase kinase-1 




investigated [29-36]. Using stably transfected HeLa cells overexpressing wild-type or mutated 
IκBα, we established that the S32, 36A mutations of the inhibitor are not necessarily 
sufficient to enhance the cytotoxicity of the drug. The wild-type IκBα can indeed be more 





2. Materials and Methods 
 
2.1. Chemicals and reagents 
All enzymes and recombinant human TNFα were from Roche. Camptothecin (CPT), 
N-acetyl-leu-leu-norleucinal (ALLN), acetyl coenzyme A and cycloheximide (CHX) were 
purchased from Sigma, thymidine from Calbiochem. E64-d and clastro-lactacystin-β-lactone 
(lactacystin) were respectively obtained from Peptide International and Boston Biochemicals.   
 
2.2. Plasmids 
The plasmids expressing the inhibitors HA-IκBα and mutated HA-IκBα (S32,36A) 
under the control of the CMV promoter were obtained from Dr V. Bours (Laboratory Medical 
Chemistry from the University of Liège). HA-tagged MEKK1 wild-type and dominant 
negative (D1369A), c-myc-tagged NIK wild-type and dominant negative (K429,430A) all four 
under the control of the CMV promotor as well as pGST-IκBα1-54 and pGST-IκBα1-54 
(S32,36A) expressing a fusion protein of GST and the 54 first amino-acid residues of IκBα 
either wild-type or mutated were kind gifts from Dr R. Gaynor (University of Texas 
Southwestern Medical Center). The κB-Luc reporter construct containing five κB sites from 
the HIV-1 long terminal repeat clone upstream of the Luciferase gene was from Stratagen and 
the expression plasmid containing the green fluorescent protein under the control of the CMV 
promotor from Clontech.  
 
2.3. Cell culture 
HeLa cells were grown in EMEM supplemented with 10% fetal calf serum at 37°C in 
a 5% CO2 atmosphere. HeLa cells stably overexpressing HA-tagged IκBα either wild-type or 
mutated at both serines 32 and 36 (S32-36A) were obtained after transfection with the 
corresponding plasmids bearing a gene conferring resistance to geneticin G418. After 2 
weeks, several clones were picked and screened for expression. A few selected clones positive 
for expression were subcloned. 
The HeLa HIV-1 CAT cell line, expressing the bacterial CAT gene under the control of the 
long terminal repeat of the HIV-1, was received form K. Valerie (Virginia Commonwealth 
University, VI) and was cultivated in identical conditions to HeLa cells. 
 
2.4. Synchronization of the cells 
For G1/S synchronization, HeLa cells were grown for 18 hours in normal medium. 
The media was then replaced by fresh media containing 2 mM thymidine for 16 hours. After 
release in thymidine-free medium, the cells were grown for 10 hours, then exposed a second 
time to 2 mM thymidine for an additional 16 hours [37;38]. To monitor cell synchrony, the 
cells were collected at different times post-release of the block by trypsinisation, fixed in 70% 
(v/v) ethanol, stained with propidium iodide and analyzed by flow cytometry on a FACS 
Calibur (Becton Dickinson). The data were analyzed with the software WINMDI version 2.8. 
  
2.5. Total, cytoplasmic and nuclear protein extracts. 
All cells were plated the day preceding the experiment except when synchronized. 
Whole cell extracts were prepared by rapid lysis of the cells (grown in 6-well plates) in 300 
µL of SDS-containing buffer (62.5 mM Tris-HCl pH 6.5, 2 % w/v SDS, 10 % glycerol, 25 
mM DTT, 0.1 % bromophenol blue). The extracts were sonicated in a water bath for 40 




Cytoplasmic extracts and nuclear extracts were prepared as described earlier [18] 
except that 0.3 % (v/v) Igepal was added to the hypotonic buffer used to obtain the 
cytoplasmic extracts. Protein concentrations were determined with the Bio-Rad protein assay. 
 
2.6. Western blotting 
The presence of inhibitors (IκBα, IκBβ and IκBε) or phosphorylated-IκBα (P-IκBα) in 
total (20 - 40 µL) or cytoplasmic extracts (10 µg) was determined by immunoblotting using 
specific antibodies as described earlier [18]. Anti-IκBα monoclonal antibody was a gift from 
C. Dargemont (Curie Institute, Paris). Anti-phospho-IκBα-S32 antibody was purchased from 
New England Biolabs. The polyclonal anti IκBβ and ΙκBε antibodies were from Santa Cruz 
Biothechnology. The rat monoclonal antibody directed against the HA epitope was from 
Roche.  
 
2.7. Electrophoretic Mobility Shift Assay (EMSA) 
Binding reactions and supershift experiments were performed with 5 µg of nuclear 
proteins and 0.2 ng of [32P] radiolabeled probe κB probe (5’- GGTTACAAGGGACTTTCC 
GCTG-3’) [18]. The dried gels were autoradiographied and in some instances the amount of 
retarded probe was quantified by Phosphorimager analysis (Molecular Dynamics). When 
supershifts were performed, 5 µg nuclear proteins and 1 µg of antibody directed against either 
p50, p52, RelA, c-Rel, RelB (Santa Cruz Biotechnology) or phosphorylated-p38 (New 
England Biolabs) were incubated on ice for 20 min prior to the addition of the radioactive 
oligonucleotide probe. The complex protein/DNA was separated from the free probe on a 6% 
native polyacrylamide gel in the regular mobility assay and on a 4% native polyacrylamide gel 
in supershift assays. For the competition experiments, 10-, 50- or 100-fold molar excess of 
either wild-type or mutated probe (5’-GGTTACAACTCACTTTCCGCTG -3’) were added to 
the incubation mixture. 
 
2.8. CAT Assays 
  CAT activity was assayed as described by Neumann et al. [39]. This method is based 
on the solubility difference in a scintillation cocktail between the substrate of the reaction, 
[3H] acetyl-coenzyme A, and the enzymatic product of the reaction, [3H] acetyl-
chloramphenicol. Only the product of the reaction diffuses in the organic phase where it can 
be detected. The CAT activity is given by the initial rate of the reaction. Three days prior to 
the drug treatment 1.3 x 105 cells were plated in 6 well tissue culture dishes. The next day, the 
synchronization process was initiated in half of the wells. CPT was added 4 hours post release 
of the second thymidine blockage and incubated for twelve hours. The cells were collected, 
washed in PBS, resuspended in 100 µL of 0.1 M Tris-HCl pH 7.8 and disrupted by three 
cycles of freezing and thawing. The extracts were centrifuged, the supernatants heated 15 min 
at 65°C and the denatured proteins precipitated. CAT activity was detected in the supernatant, 
48 µL of supernatant was mixed to 198 µL of 1.25 mM chloramphenicol and 0.5 µCi [3H]-
acetyl coenzyme A (NEN Life Science Product) diluted with carrier acetyl CoA to 0.1 mM. 
The mixtures were overlaid with 5 mL EconoFluor (Packard) and the vials counted 
continuously in a liquid scintillation counter (Wallac) to generate kinetics of chloramphenicol 
acetylation.  
 
2.9. Immunoprecipitation and in vitro kinase assay 
Drug-treated and control HeLa cells were lysed in 10 mM HEPES-KOH pH 7.9, 3 mM 
EDTA, 10 mM KCl, 0.3 % (v/v) Igepal, 0.5 mM PMSF, 1 mM DTT, containing phosphatase 




phosphate) and protease inhibitors (Complete® from Roche). After 20 min incubation on ice, 
the lysate was vortexed and centrifuged at 15000 g, for 5 min at 4°C. The supernatants 
containing the cytoplasmic proteins (250 µg) were then incubated 2 hours at 4°C with 1 µg 
anti-IKKα antibody in 50 mM Tris-HCl pH8.0, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 
0.1 % (v/v) Igepal plus all protease and phosphatase inhibitors described above. Finally 15 µL 
of protein A Sepharose beads (Pharmacia) were added and the incubation continued for a 
further 16 h at 4°C. The immunoprecipitates were washed 3 times in the incubation buffer and 
twice in kinase buffer containing 50 mM Tris–HCl pH 8.0, 100 mM NaCl, 2 mM DTT and 
the protease and phosphatase inhibitors. The immunoprecipitated proteins were then incubated 
with 0.5 µg GST-IκBα1−54 or GST-IκBα1-54 (S32,36A) and 10 µCi ATP-γ-[32P] (ICN), in the 
kinase buffer for 30 min at 30°C. The reaction was stopped by addition of the Laemmli’s 
sample buffer. The eluted proteins were subjected to a 12 % (w/v) SDS/PAGE. The gel 
stained by Coomassie blue to visualize the amount of substrate, was dried and 
autoradiographied.  
 
2.10. Transient transfection assays 
       HeLa cells (3 x 105) were placed in 6 well-plates 24 hours prior to the transfection and 
grown in regular media. The transfections were effectuated with Fugene 6TM (Roche) 
according to the manufacture procedures except that the ratio (µL FUGENE/ µg ADN) was 
2.5 instead of 3. Cells were transfected with 100 ng of plasmid bearing the κB-LUC insert and 
increasing amount of plasmid expressing the kinase inactive mutant of NIK or MEKK1. Six 
hours and a half after transformation, the media was replaced and the cells treated with TNFα 
(200 U) or CPT (3 µM) for 12 hours. The cells were then washed in PBS, scraped, lysed for 
15 min at room temperature, and centrifuged at 15000 x g for 10 min at 4°C. The Luciferase 
activity of the supernatant was measured with the Luciferase Reporter Kit from Roche. The 
values obtained were corrected for the amount of protein.  
 
2.11. Determination of cellular viability 
Stably transformed cells were seeded at the concentration of 3000 cells par well in flat-
bottomed 96 well plates and cultivated with 0.2 mL medium. The cells were grown for 24 
hours without geneticin G418, then the media was removed and fresh media containing 
appropriated concentrations of CPT was added. After 48 hours of incubation with the drug; 
cell viability was measured by a colorimetric assay based on the cleavage of the tetrazolium 





3. Results  
 
3.1. NF-κB DNA binding activity induced by CPT 
To study NF-κB activation by CPT, we examined the induction of NF-κB DNA 
binding activity in nuclear protein extracts by EMSA. Exponentially growing HeLa cells were 
treated with a single dose of TNFα (200 U/ mL) or CPT (10 µM) for increasing period of 
time. This CPT concentration is compatible with the plasma concentrations observed 
immedialy after the injection of the compound (7.7µM for Irinotecan a soluble analog of CPT 
in human and 5.8 µM for CPT in mice) [Rhône Poulenc Rhorer and [40]]. The cells were kept 
in contact of the drugs for the entire duration of the incubation. Contrarily to the rapid NF-κB 
induction observed after addition of TNFα [25;41] (Fig. 1A, lanes 1-6, top panel), the CPT-
induced NF-κB binding activity was much slower and more stable (Fig. 1A, lanes 7-14, top 
panel). NF-κB response elicited by TNFα was maximal after 20 min, sustained for 1 hour, 
then began to decline; whereas NF-κB was first detected one hour after exposure to CPT and 
increased steadily until it reached a maximum after about 2-3 hours. The induction was 
maintained for many hours and was still detectable after 24 hours (Fig. 1A, lane 14). The 
activation of NF-κB by CPT is observed with concentration of CPT as low as 0.1µM and 
increases as the drug concentration is augmented (data not shown and Fig. 1B in ref. 13). 
The specificity of the DNA/protein complexes formed two hours after the addition of 
CPT was ascertained by competition assay (Fig. 1B). The slower migrating complex was 
efficiently competed away by as little as a 10-fold excess of the unlabelled κB probe and 
completely abolished by a 50-fold or 100-fold excess but not by the same excess of an 
unlabeled mutated κB oligonucleotide. The faster migrating complex was unaffected by either 
probes. 
As the CPT-induced activation of NF-κB is slow in regard of the cellular response 
produced by TNFα, the induction pathway of NF-κB used by CPT could have required the 
synthesis of de novo proteins. But as already reported earlier in other cell types CEM and 
70Z/3 [13;15], the incubation of HeLa cells for 30 min with cycloheximide (CHX) a 
traduction inhibitor, prior to CPT addition, did not modify the intensity of the DNA/protein 
complex indicating that no protein synthesis is required. Under these conditions, the CHX did 
not activate NF-κB neither did it modify the level of IκBα (data not shown). 
The long lasting induction of NF-κB incited us to compare the nature of the specific 
protein/DNA complex obtained 6 hours after CPT addition, with the composition of the 
complex formed after 2 hours and 24 hours. After 6 hours, the specific complex contained 
mostly p65 (RelA), p50 and p52 as the apparition of supershifted bands correlated with a 
partial depletion of this complex (Fig. 1C, lanes 2, 3 and 4). A supershifted band was also 
detected using anti-c-Rel antibodies but without apparent diminution of the specific complex 
indicating that c-Rel is a minor component (Fig. 1C, lane 5). No supershifted bands were 
detected either with anti-RelB antibody or the non-related anti-phosphorylated-p38 antibody 
(Fig. 1C, lanes 6, 7). After 2 hours, the complex had a similar composition but with a smaller 
representation of p52 (data not shown) and was thus mostly constituted of p50 and p65. After 
24 hours, the nature of the complex was different, p52 being the predominant species present 
(Fig. 1C, lane 11). The relative amount of p50, p65 and c-Rel supershifted decreased (Fig. 1C, 
lanes 9, 10, 12) and the complex was disrupted by anti-RelB antibody indicating the presence 
of RelB (Fig. 1C, lanes 13). Thus the complex composition evolved with time. At first, the 
heterodimer p50/p65 is the major subset represented then is substituted by p52 and RelB.  
 




As the cytotoxic effect of CPT is maximal for S phase cells [4], we compared the NF-
κB induction in a randomly growing population and in synchronized cells. HeLa cells were 
synchronized by forcing an arrest at the G1/S border by exposition to an excess thymidine. 
Four hours after the release of the block, a majority of HeLa cells were in S phase of the cell 
cycle as confirmed by FACS analysis (Fig. 2A). The proportion of cells in G1, S and G2 were 
respectively of 62%, 11%, 22% in the random population and of 15%, 55% and 21% in the 
synchronized population.  A direct comparison between the signal detected in S phase or 
randomly growing cells, 4 hours after the addition of CPT, revealed that NF-κB activation, 
measured by the radioactivity associated with the specific complex, was 4 fold more important 
in the synchronized cells (Fig.2B, lanes 2 and 4). The procedure of synchronization did not 
elevate the basal level of NF-κB significantly (Fig. 2B; lanes 1 and 3). The kinetic of 
induction of NF-κB in S phase synchronized cells was similar to the one observed in 
randomly growing cells (Fig. 2C and 2D top panels).  NF-κB binding activity was still slow to 
appear  (Fig. 2C, top panel) and stable for many hours (Fig. 2D, top panel).   
In order to see whether the enhanced NF-κB induction observed in S phase cells was 
reflected at the transcriptional level, we used the HeLa HIV-1 CAT cell line. In this cell line, 
the bacterial CAT gene with a polyadenylation signal was placed under the control of the HIV-
1 long terminal repeat. Three days prior to the drug treatment 1.3 x 105 cells were placed in 6 
well tissue culture dishes. The next day, the synchronization process was initiated in half of 
the wells. Four hours after the release from the thymidine blockage, CPT (3.3 µM) was added 
and incubated for 12 hours. At the end of the incubation period, the level of CAT activity 
present in the cells was measured. As shown in Fig. 2E, representing the initial rates of release 
of [3H] acetyl-chloramphenicol, the NF-κB induced by CPT is transcriptionally active as the 
level of CAT activity increased in response to CPT (compare triangle to square symbols). For 
an identical CPT concentration (3.3 µM), there is a 2.2 fold stimulation of the CAT activity 
induced when the cells are in S phase. Under these experimental conditions, the values of the 
initial rate of reaction calculated between 66 and 102 min were of 636 cpm/min and 288 
cpm/min for the CPT treated S phase cells or randomly growing cells respectively. In control 
cells, exempt from CPT treatment, the basal level of CAT activity was not affected by the 
synchronization process (compare closed and open square).  
 
3.3. Time course of CPT-induced degradation of the IκB family members  
In a first time, the level of cytoplasmic IκBα was followed in extracts from 
asynchronous HeLa cells, treated either with TNFα or CPT for increasing periods of time 
(Fig. 1A, bottom panel). As already described by others [25;41] TNFα (200 U/ mL) induced a 
rapid and transient degradation of IκBα (Fig. 1A, bottom panel, lanes 1-6). The level of 
degradation of IκBα following CPT treatment was much weaker and in some experiments not 
detected at all (Fig. 1A, bottom panel, lanes 7-14). In a second time, cytoplasmic extracts from 
mostly S phase cells treated with CPT were analyzed for their content in IκBα  up to three 
hours after addition of CPT (Fig. 2C, bottom panel) or for longer lengths of time (Fig. 2D,  
second panel). 
Under these conditions, the depletion of cytoplasmic IκBα is almost complete and long 
lasting. Thus, the level of degradation of IκBα is more pronounced for cells in S phase than 
for random cells. The re-synthesis IκBα is observed about 6 hours after CPT addition, this re-
synthesis precedes of many hours the disappearance of NF-κB induction. This is why, we also 
examined the level of two other inhibitors IκBβ and IκBε in cytoplasmic extracts (Fig. 2D, 




IκBε does not seem to be degraded. Its level detected 24 hours after the addition of CPT is in 
fact higher that at the beginning of the reaction. 
 
3.4. CPT-induced phosphorylation of IκBα  
In order to determine whether the signal transduction initiated by CPT has other 
common steps with the cascade of events initiated by TNFα, we monitored the 
phosphorylation of the serine 32 of IκBα. The presence of phosphorylated IκBα (P-IκBα) was 
followed in total cellular extracts by Western blotting with a polyclonal antibody raised 
specifically against IκBα posphorylated on serine 32. S phase cells were treated with TNFα 
(1000 U/ mL) or CPT (10 µM) for the indicated time (Fig. 3A). P-IκBα was detected both in 
response to TNFα and CPT. The time course of apparition and the quantity formed are 
however quite different. After TNFα treatment, P-IκBα is rapidly (5 min) and transiently 
detected. Fifteen min after the addition of TNFα the amount of P-IκBα is already decreasing. 
After CPT treatment, the generation of P-IκBα is slower, none is detected after 30 min, its 
level is maximal after 60 min and then decreased. Its presence is still detectable at 90 min. 
Phosphorylated IκBα was undetectable in a randomly growing cell population (data not 
shown). The apparition of P-IκBα is preceding the NF-κB induction. It is maximal 60 min 
after CPT addition whereas NF-κB activation reaches a maximum after 2, 3 hours. 
 
3.5. Activation of the endogenous IKK by CPT  
Endogenous IKK kinase activity was monitored following immunoprecipitation with 
an anti-IKKα antibody that precipitated the IKKα /IKKβ / ΙΚΚγ complex. Cytoplasmic 
extracts from S phase synchronized cells treated either with TNFα or CPT were tested. The 
immunoprecipitated proteins were incubated with GST-IκBα 1-54 or its mutated version in 
presence of ATP-γ-[32P]. A strong activation of the IKK kinase by TNFα was detected after a 
very short time (Fig. 3B, top panel lanes 5, 6) [29;41]. Whereas the CPT–related activation of 
the IKK was much weaker. The kinase activation was sustained for as long as two hours (Fig. 
3B, top panel, lanes 1-4). Once again, we could not detect any activation of the IKK complex 
in a randomly growing cell population (data not shown). Although the level of P-IκBα was 
maximal 60 min post CPT-addition (Fig. 3A) and weaker after 90 min, the level of activation 
of the IKK is stable at least for 2 hours. It could reflect an equilibrium between a stable 
activation of the IKK kinases by CPT and an increasingly efficient degradation of P-IκBα or a 
deficit in IκBα. The CPT-induced phosphorylation of IκBα seemed to be classically targeted 
on S32 and S36, no incorporation of radioactivity was detected on the mutated GST-IκBα1-52 
(S32,36A) (Fig. 3B bottom panels). 
 
3.7. Requirement of S32 and S36 in the CPT-induced degradation of IκBα  
In order to make certain IκBα degradation relies on S32 and S36, we generated HeLa 
cells stably expressing an epitope tagged HA-IκBα or its mutated form HA-IκBα (S32,36A). 
A control population of HeLa cells stably transfected with the empty vector was also 
established. Four clones expressing either low or high level of the inhibitor were selected and 
subsequently sub-cloned (Fig. 4A). Both CPT-related NF-κB DNA binding activity and IκBα 
degradation were studied on these clones.  
At low level expression, the exogenous HA-IκBα did not modify the NF-κB induction, 
the same activation was observed in these cells and in the control cells expressing no HA-
IκBα (Fig. 4B, upper panel, lanes 1-5 and 6-10). On the opposite, in the clonal population 
expressing a very large quantity of HA-IκBα, NF-κB induction was completely abolished 




were totally repressed. Similar results were obtained with the clones expressing mutated HA-
IκBα (S32,36A). At low level expression, the mutated IκBα did not alter the induction of NF-
κB (Fig. 4B, lower panel, compare lanes 1-5 to lanes 6-10) whereas the binding activity was 
partially repressed in the clone expressing high level of mutated HA-IκBα  (Fig. 4B, lower 
panel, lanes 11-15). In this case, the signal was not completely abolished because of the lesser 
level of expression of the HA-IκBα (S32,36A) (Fig. 4B, lanes 2 and 4). 
The CPT-induced degradation of wild-type HA-IκBα can be seen in both low and high 
level expressing clones (Fig. 4C, top panels). The level of HA-IκBα steadily decreased with 
time over the period tested, no accumulation of the phosphorylated form was noticeable 
suggesting that the ubiquitination and degradation machinery is able to process P-HA-IκBα as 
it appears. The slower mobility form of HA-IκBα corresponding to the phosphorylated HA-
IκBα is apparent following TNFα treatment. Its presence indicates - i) that the exogenous 
HA-IκBα is efficiently recognized and phosphorylated by the kinase – ii) that the proteasome 
is unable to degrade the P-IκBα as quickly as it is generated. The apparent lack of HA-IκBα 
degradation in the high level expression clone may be explained by the very high level of 
expression of the inhibitor, its degradation by the 26S proteasome may go unnoticed if it 
corresponds to the degradation of a small fraction of the HA-IκBα. 
The analysis of both clones expressing low and high level mutated HA-
IκBα (S32,36A) indicated that the mutated inhibitor was resistant to the degradation induced 
by TNFα as well as by CPT. The data presented above confirmed that CPT-induced 
degradation of IκBα requires the presence of S32 and/ or S36. 
 
3.8. Involvement of the 26S proteasome in the signal transduction  
It is well known that the 26S proteasome is responsible (only partially in some cell 
types) of the degradation of P-IκBα after TNFα treatment [42]. To verify the role of the 26S 
proteasome in the CPT-related degradation of IκBα, we first used ALLN. This tripeptide 
aldehyde is known to inhibit the 26S proteasome, calpain and cathepsin B  [43;44] and was 
employed with success to stabilize P-IκBα after different stimuli such as TNFα and UV [27]. 
In the following experiments, HeLa cells were or were not pre-incubated 45 min with ALLN 
prior to the incubation with TNFα or CPT. As can be seen in Fig. 5A (lanes 5, 6), the ALLN 
pre-treatment has a very strong effect on the CPT related NF-κB activation. The diminution of 
the NF-κB induction in response to CPT is even more pronounced that the decrease observed 
in the TNFα treated cells (lanes 2, 3). The stabilization of P-IκBα was monitored in 
cytoplasmic extracts of S phase cells (pretreated or not). As can be seen on the top panel of 
Fig. 5B, the ALLN pre-treatment stabilized the phosphorylated forms of IκBα both after 
TNFα and CPT treatments (compare lanes 2 with 3 and 5 with 6). Two slow migrating bands 
are stabilized in the ALLN/TNFα treated cells (lane 3), they could represent the successive 
phosphorylation of the two serines 
As already mentioned earlier in this paragraph, ALLN is not a specific inhibitor of the 
26S proteasome. Thus, in order to study more precisely the events observed we used two 
different specific inhibitors: lactacystin (specific of the 26S proteasome) and E64-d (specific 
for calpain). S phase synchronized cells were pre-incubated or not with one of these inhibitors 
45 min prior to TNFα or CPT addition and the level of P-IκBα was monitored in total cellular 
extracts. The stabilization of P-IκBα was detected in Lactacystin/TNF-treated cells (Fig. 5B, 
middle panel, lanes 2-4) and in Lactacystin/CPT treated cells (lanes 5 and 6). The calpain 





3.9. Inhibition of CPT-induced NF-κB activation by kinase deficient NIK 
Next, the involvement of NIK in the cascade of events between the CPT induced DNA 
damage and the activation of NF-κB was investigated. NIK was originally identified as a 
TRAF2 interacting protein. It interacts strongly with IKKα [29-30]. When overexpressed, 
NIK constitutively activates NF-κB whereas kinase inactive mutant of NIK blocks NF-κB 
activation by TNFα  [31-35].  
Exponentially growing HeLa cells were co-transfected with the κB-Luc expression vector and 
increasing amount of a kinase deficient NIK mutant (K429,430A), then subsequently treated 
with TNFα (200 U/ mL) or CPT (3 µM). The Luciferase activity was measured in total 
cellular extracts prepared 12 hours after the addition of the drugs. As can be seen on Fig. 6A, 
the activation of NF-κB by CPT was efficiently blocked by this kinase deficient NIK. 
Moreover, this inhibition is dose dependent. It suggests that NIK is required for the CPT 
induced NF-κB activation. As expected, the NF-κB activation elicited by TNFα is also 
blocked. 
The effect of kinase deficient MEKK1 was evaluated in a similar manner. In this case, 
however the CPT elicited activation of NF-κB was not inhibited, the level of Luc activity 
remained more or less constant, a slight activation was observed (Fig.6B). 
 The interference of mutated NIK on the activation of the IKK by CPT was also 
examined. HeLa cells were synchronized and transfected with a high amount of either mutated 
MEKK1 or mutated NIK or with a carrier vector. The transfection efficiency was monitored 
by fluorescence. Under the conditions used, 50% of HeLa cells, transfected with a plasmid 
expressing the fluorescent green protein were fluorescing 24 hours after the transfection. 
Twenty-four hours after the transfection, the transfected cells were treated with CPT (10 µM) 
for 80 min and the kinase activity was detected in the fraction of proteins immunoprecipitated 
by anti-IKKα antibodies. As shown in Fig. 6C, the level of activation of the IKK was 
decreased in the cells expressing mutated NIK. The amount of radioactivity present in each 
spot was quantified by phosphorimaging analysis. If an arbitrary value of 100 is given to the 
amount of radioactivity incorporated in GST-IκBα by the extract derived from the CPT 
treated cells, that amount drops to 52 for the cells expressing mutated NIK. 
 
3.10. Cytotoxicity of CPT 
To determine whether the overexpression of IκBα or mutated IκBα influences the 
cytotoxicity of CPT, we measured the viability of these cells after 48 hours exposition to 
different CPT concentration (0.1 µM- 1 µM). A low expression level of wild-type IκBα did 
not significantly affect the cellular resistance to CPT whereas large overexpression of the 
inhibitor markedly increased its sensibility (Fig. 7A). At 0.1 µM the survival of the cells 
expressing only the endogenous IκBα was 72%, whereas the cells expressing low level of 
exogenous IκBα or the high level had a survival rate of 77% and 11% respectively. The 
expression of either low or high level of mutated IκBα had a minor negative effect on the 
survival (Fig. 7B). At 0.6 µM, the cells overexpressing a large quantity of mutated IκBα had a 





4. Discussion  
The goal of this study was to determine the intermediate steps of the activation of NF-
κB following CPT-induced DNA damage and to further define the kinetics of these steps. As 
the sole target of this drug is DNA-topoisomerase I, the nature of the initial damage is well 
defined and limited to DNA single- and double-strand breaks. The resulting signal 
transduction could have been entirely different of the one observed with the cytokine TNFα, 
which originates at the level of the membrane receptor TNF-R1. However, it was shown that, 
thought the signal does not originate from the same cellular compartment and though the 
kinetic of NF-κB inductions is different, both signaling cascades share common intermediates. 
The activation of the IKK complex, the phosphorylation of the inhibitor IκBα on S32 and S36 
and its subsequent degradation, and the participation of the 26S proteasome are observed in 
both signal transductions. This indicates that, early in the transduction cascade elicited by 
CPT, a signal transfers from the nuclei into the cytosol. Another study reached the same 
conclusion [15].  Ionizing radiation, generating double-strand breaks, induce NF-κB in a 
rather similar manner than CPT. The IR-induced NF-κB activation is also slow and rely on the 
phosphorylation of both S32 and S36 of IκBα as well as the participation of the 26S 
proteasome [27].  
By supershifting the protein/DNA specific complex with antibodies, we have shown 
that CPT treatment activated multiple NF-κB DNA binding complexes, and that the nature of 
these complexes evolved with time. At first, after two hours, mostly p50 and p65 were present 
with p52 and c-Rel in little amount; the heterodimers formed were very likely the same as 
those identified after TNFα induction in HeLa cells (p50/p65, p52/p65, p50/c-Rel and p52/c-
Rel) [45]. IκBα being principally complexed to the p50/p65 heterodimer in the cytosol, its 
degradation will lead to the transfer of this specific heterodimer in the nuclei. Then, as time 
goes, we observed more and more p52 and the apparition of RelB. This sequential evolution 
of the complex was likely to result from the subsequent degradation of the other IκB 
inhibitors. As the nature of the dimers dictates its affinity to the consensus κB sequences, the 
induction of different subsets of the Rel family modifies the target genes [46-48]. It was noted 
that IκBα resynthesis preceded of many hours the inactivation of NF-κB. IκBβ whose 
degradation is less pronounced but long lasting is probably responsible for the late NF-κB 
activation. In resting cells, IκBβ and ε are associated with large amount of RelA and c-Rel 
[49]. We could not detect any substential degradation of IκBε.  IκBε however was inducible 
by CPT treatment as it level was more elevated 24 hours after the addition of the drug than in 
the control cells.  
One principal characteristic of CPT is its cytotoxicity specifically associated with the S 
phase of the cell cycle. The consensus in the literature was that lethal double-strand breaks are 
created by the collision of the replicative machinery with cleavable complexes, thus 
concentrating the formation of these lethal lesions in S phase. But a recent study seems to 
indicate that the number of double-strand breaks is not the only decisive factor, that in fact the 
post DNA damage pathway activated by the cells could be different in S phase than in other 
phases of the cell cycle [50]. Studies with AT cells, where the kinetic of NF-κB activation 
following CPT treatment is modified, also indicated the importance of these post DNA 
damage events [14]. This hypothesis might be further reinforced by a recent observation 
indicating that, following ionizing radiation, ATM phosphorylated nibrin (the protein 
deficient in the Nijmegen Breakage Syndrome) at an S-phase internal check-point [51]; thus, 
confirming the existence of a S phase specific event in the cellular response to double strand 
breaks. In this work, we have shown that the CPT-induced NF-κB activation is principally 




in S phase synchronized cells by comparison with a randomly growing population. The NF-
κB transcriptional activity induced by CPT (detected by CAT assay) is stimulated 2.2-fold in 
S phase synchronized cells. This lack of proportionality between NF-κB activation and its 
transcriptional activity could be due to the difference in the length of time between the 
addition of the drug and the preparation of the extracts in the two different assays. Other 
arguments confirmed the S phase dependence: i) the activation of the IKK kinases is stronger, 
ii) higher quantity of P-IκBα are detected and iii) the degradation of IκBα (hardly observable 
in a non-synchronized population) is almost complete when cells are in S phase. The lag 
between CPT addition and NF-κB apparition in the nuclear extracts is not reduced in S phase 
cells, indicating that the NF-κB induction detected in the random population reflects what 
happens in S phase.  
In general, the ubiquitin proteasome pathway plays an important role in two aspects of 
the NF-κB activation. It participates to the generation of p50 and p52 subunits, which are 
principally generated by a co-translational proteolytic processing, and it degrades 
ubiquitinated phosphorylated IκBα, β and ε [52-54]. We observed that ALLN and lactacystin 
stabilized P-IκBα after TNF and CPT treatment. In the signal transduction specific to CPT, 
the proteasome could yet act at additional levels. Indeed, it was reported that 10 min post CPT 
addition, 10% of the DNA-topoisomerase I involved in the cleavable complexes was multi-
ubiquitinated and then degraded by the proteasome [55;56]. This degradation could be a 
crucial step of the signal transduction. However, the ubiquitination of the topoisomerase I 
trapped in the cleavage complex was recently challenged. Other authors reported that CPT 
induces a rapid and extensive conjugation of SUMO-1 to DNA topoisomerase I and that 
proteases different from the 26S proteasome are involved in this pathway [57]. In a recent 
publication it was shown that the cellular response to a proteasome inhibitor treatment 
associated to CPT was different if the inhibitor treatment preceded the CPT addition or if it 
followed it [58]. And finally, it has to be kept in mind that the proteasome also participates in 
cell cycle progression and could also interferes with the CPT-induced NF-κB activation by 
blocking the cell in a non reactional phase [59;60]. 
 
The activation of the IKK complex is presently under intensive scrutiny. Either 
upstream activating kinases are necessary or IKK, stimulated by the transient association with 
other partners in a multiprotein complex, autophosphorylates and autoactivates. Based upon 
the studies involving overexpression of recombinant proteins, two kinases MEKK1 and NIK 
have been shown to interact with and to activate the IKK complex. Using dominant negative 
NIK and MEKK1, we studied the effect of these two mutated kinases on the CPT induced NF-
κB activation. Only the overexpression of NIK (K429,439A) negatively regulated the 
activation of NF-κB ; thus indicating the participation of NIK in the signaling cascade. The 
reduced level of activation of IKK, monitored in a kinase assay, confirmed the negative 
interference of mutated NIK in the CPT-induced signaling cascade. Activated NIK could 
interact with other proteins i.e. (receptor interacting protein) RIP with the IKK [61].  
Finally, we observed that the ectopic overexpression of wild-type IκBα can have a 
stronger influence on the survival rate of the cells, than the overexpression of the mutated 
inhibitor. In the clone expressing HA-IκBα 10- to 15- fold over the level of the endogenous 
IκBα,  the induction of NF-κB was completely abolished after both TNFα and CPT 
treatments. It indicates that the prevention of NF-κB activation can be achieved very 
efficiently by overwhelming the degradation capacity of the proteasome and that, in HeLa 




Our results contribute to a better understanding of the few steps immediately preceding 
the activation of NF-κB in the cascade of events initiated by CPT related DNA damage. The 
exact nature of the S phase specific step leading to the activation of the IKK, as well as the 
nature of the signal leaving the nuclei are still under investigation. The precise knowledge of 
every steps implicated in this signal transduction would bring valuable information for the 
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Fig. 1. Activation of NF-κB and degradation of IκBα elicited by TNFα or CPT in HeLa cells.  
A) Upper panel:  NF-κB DNA binding activity. 
5 µg of nuclear extracts derived from exponentially growing HeLa cells, non-treated (lanes 1 
and 7), treated with TNFα (200 U/ mL) (lanes 2-6) or treated with CPT (10 µM) (lanes 8-14) 
for the indicated length of time were tested for their ability to retard a [32P]-radiolabeled 
oligonucleotide (0.2 ng) containing the κB consensus sequence. Migrating position of the 
specific NF-κB/DNA complexes (sp) and non-specific protein/DNA complex (nsp) are 
indicated. 
Bottom Panel: Stability of IκBα. 
Cytoplasmic extracts derived from the same cells were analyzed for their content in IκBα. 
Proteins (10 µg) were separated on a 10 % polyacrylamide gel and immunoblotted with anti-
IκBα antibodies. Lanes 1 and 7: non-treated cells; lanes 2-6: cells treated by TNFα for 10, 20, 
40, 60, 120 min; lanes 8-14: cells treated by CPT for 30, 60, 120, 180, 240, 360 min and 24 
hrs. The position of IκBα is indicated. 
B) Specificity of the NF-κB complexes induced by CPT. 
Nuclear extracts prepared from HeLa cells treated 2 hours with CPT (10 µM) were incubated 
with the [32P] radiolabeled probe in the usual conditions (lane 1), with a 10-, 50-, 100- fold 
excess of the unlabeled wild-type κB probe (lanes 2-4) or with a 10-, 50-, 100- fold excess of 
an unlabeled κB mutated probe (lanes 5-7). 
C) Nature of the NF-κB complexes induced by CPT. 
Nuclear extracts from HeLa cells, treated 6 hours (lanes 1-7) or 24 hours (lanes 8-14) with 
CPT 10 µM, were incubated for 15 min on ice in the binding buffer alone (lanes 1 and 8) or 
with antibodies directed against p50 (lanes 2 and 9), p65 (RelA) (lanes 3 and 10), p52 (lanes 4 
and 11), c-Rel (lanes 5 and 12) and RelB (lanes 6 and 13) or phosphorylated p38 (lanes 7 and 
14). After that time, the [32P] oligonucleotide probe was added and the incubation continued at 
room temperature for an additional 30 min. The specific complexes and the supershifted 
bands are respectively indicated by sp and a bracket. 
 
Fig. 2.  S phase dependence in NF-κB activation by CPT. 
A) FACS analysis of asynchronous or synchronized cell populations. 
Exponentially growing HeLa cells asynchronous (left panel) or synchronized (right panel) 
were trypsinized, fixed, stained with propidium iodide and analyzed by FACS for relative 
DNA content. The synchronized cells were collected 4 hours post release of the thymidine 
block. The position of the peaks G1, S and G2 are indicated. 
B) Comparison of the NF-κB activation in randomly growing cells and S phase cells. 
Nuclear extracts derived from asynchronous (lanes 1, 2) or S phase synchronized (lanes 3, 4) 
cells treated 4 hours with CPT (10 µM) (lanes 2 and 4) were tested by EMSA.  
C) Activation of NF-κB and degradation of IκBα by CPT in S phase cells. 
Upper panels: NF-κB DNA binding activity. 
Four hours post-release of the thymidine block, CPT (10 µM) was added to the S phase 
synchronized cells. At the indicated time after CPT addition, nuclear extracts were prepared 
and the NF-κB DNA binding activity was determined by EMSA. The migrating position of 
the specific NF-κB/DNA complexes (sp) and non-specific protein/DNA complex (nsp) are 
indicated. 




For the detection of IκBα, 10 µg of cytoplasmic extracts, prepared from the same S phase 
synchronized cells, were analyzed by immunoblotting with anti-IκBα antibodies. Extracts 
from non-treated control cells are in lane 1. 
D) Long term CPT-induced activation of NF-κB and degradation of IκB  in S phase cells  
Upper panels: NF-κB DNA binding activity. 
As reported in Fig. 2C over a longer length of time. 
Lower panels: IκB degradation induced by CPT in S phase cells. 
IκBα, IκBβ and IκBε were detected in 10 µg of cytoplasmic extracts, prepared from the same 
S phase synchronized cells, by immunoblotting with anti-IκBα, -IκBβ or -IκBγ antibodies. 
Extracts from non-treated control cells are in lane 1. 
 
E) Transcriptional activity of NF-κB in randomly growing cells or S phase synchronized 
cells. 
HeLa HIV-1 CAT cells were plated in 6 well tissue dishes and synchronized or not. Four 
hours after the release of the thymidine block, both cell populations were treated for 12 hours 
with CPT (3.3 µM) or not. The CAT activity was measured in total extracts prepared from 
asynchronous (open symbols) or S phase (closed symbols) HeLa HIV-1 CAT cells. CPT 
treated cells are represented by triangles, control cells by squares.  
 
Fig. 3.  CPT induces the phosphorylation of IκBα by the IKK. 
A) CPT induces the phosphorylation of IκBα . 
Total cellular extracts were prepared from S phase HeLa cells incubated 5, 10, 15 min with 
1000 U/ mL of TNFα (lane 2-4) or 30, 60, 90 and 120 min with CPT 10 µM (lanes 5-8). 
Extracts from non-treated cells are in lane 1. The presence of P-IκBα was monitored with an 
antibody directed against IκBα−phosphorylated on S32. CPT was added to the synchronized 
cells 4 hours after the release of the thymidine block. The positions of P-IκBα  and from a non 
specific (ns) band are indicated. 
B) Endogenous IKK kinases are activated by CPT. 
S phase synchronized cells were either non-treated (lane 1), treated with CPT (10 µM) for 40, 
80, 120 min (lanes 2-4) or with TNFα (1000 U/ mL) for 5 and 7 min (lanes 5 and 6). After 
treatment, cytoplasmic extracts were prepared and immunoprecipitated with an anti-IKKα 
antibody. The IKK kinase activity in the immunoprecipitated proteins was assayed on either 
the wild-type GST-IκBα 1-54 (upper panel) or mutant GST-IκBα1-54(S32,36A) (lower panel).  
 
Fig. 4.  Serines 32 and 36 of IκBα are essential for CPT induced degradation. 
A) Stable overexpression of HA-IκBα or mutated HA-IκBα (S32,36A) in HeLa cells. 
Cytoplasmic extracts (10 µg) were analyzed by immunoblotting. Lane 1, HeLa cells 
transfected with the control vector; lanes 2 and 3, two selected clones expressing different 
amounts of mutated HA-IκBα (S32,36A); lanes 4 and 5, two selected clones expressing 
different amounts of exogenous HA-IκBα.  
B) Overexpression of wild-type or mutated IκBα modifies the induction of the NF-κB. 
Upper panel: Nuclear extracts from clonal populations expressing no exogenous HA-IκBα 
(lanes 1-5), low level of HA-IκBα (lanes 6-10) or high level HA-IκBα (lanes 11-15) were 
tested for their ability to retard a κB probe in an EMSA after various stimulation. The 
asynchronous stably transfected HeLa cells were either non-treated (lanes 1, 6, 11), treated by 
TNFα for 30 min (200 U/ mL) (lanes 2, 7, 12) or treated with CPT (10 µM) for the indicated 




Lower panel: Nuclear extracts derived from clonal populations expressing no exogenous HA-
IκBα (lanes 1-5), low level of mutated HA-IκBα ( S32,36A) (lanes 6-10) or high level of HA-
IκBα (S32,36) (lanes 11-15) were analyzed after TNFα or CPT stimulations as described 
above. 
C) S32 and S36 are required for CPT-induced degradation of IκBα 
Top panels: HeLa cells with low level expression of wild-type HA-IκBα (left panel) or high 
level expression of HA-IκBα (right panel) were treated by TNFα (200 U/ mL) for 30 min or 
by CTP (10 µM) for 1, 2 or 3 hrs as indicated. Cytoplasmic extracts were analyzed by 
immunoblotting; 10 µg were analyzed on the left panel and exceptionally only 1 µg on the 
right panel as the level of overexpression of the exogenous HA-IκBα was very high. HA-
IκBα and  P-HA-IκBα are indicated.  
Bottom panels: HeLa cells with low level expression of HA-IκBα  (S32,36A) (left panel) or 
high level expression of HA-IκBα (S32,S36A) (right panel) were treated by TNF-α (200 U/ 
mL) for 30 min or by CTP (10 µM) for 1, 2 or 3 hrs as indicated. 10 µg cytoplasmic extracts 
were loaded on both panels. 
 
Fig. 5.   Importance of the 26S proteasome in the signal transduction 
A).  ALLN blocks the CPT related NF-κB activation. 
Synchronized HeLa cells were incubated with ALLN (100 µM) for 45 min (lanes 3, 4, 6) or 
left untreated (lanes 1, 2, 5) then subsequently treated either with TNFα (1000 U/ mL) for 30 
min (lanes 2, 3) or CPT (10 µM) for 2 hours (lanes 5, 6) or left untreated (lanes 1, 4). Nuclear 
extracts (5 µg) prepared from these cells were tested for their ability to retard a [32P]-
radiolabeled probe containing the κB consensus sequence (0.2 ng). The position of the 
specific protein/DNA complexes and non specific complexes are indicated by sp and nsp 
respectively. 
G) Participation of the proteasome 26S. 
Upper panel: The presence of IκBα and P-IκBα was followed by immunoblotting of 
cytoplasmic extracts prepared in presence of a cocktail of phosphatase and protease inhibitors. 
The proteins (20 µg) were separated on a long 12 % SDS polyacrylamide gel to optimize the 
separation of IκBα and P-IκBα. The position of both IκBα and P-IκBα are indicated.  
Middle and Lower panels: The presence of IκBα and P-IκBα was monitored in total cellular 
extracts derived from S phase cells treated with 10 µg/ mL Lactacystin for 45 min (lanes 3, 4 
and 6 upper panel) or 25 µg/ mL E64 d for 45 min (lanes 3, 4 and 6 lower panel) prior to 
incubation with 1000 U/ mL TNFα for 30 min (lanes 2, 3) or 10 µg/ mL CPT for 2 hours 
(lanes 5, 6). The immunoblots were probed with anti-IκBα antibodies.  
  
Fig. 6.  Dominant negative NIK mutant blocks NF-κB activation by CPT. 
A) HeLa cells were plated in 6 well tissue culture dishes. Following an overnight incubation, 
the cells were co-transfected with the κB reporter plasmid (200 ng) and the indicated amount 
of the vector expressing the catalytically inactive NIK (K429,430A). Decreasing amounts of 
carrier vector were added to maintain the DNA load constant. Six and a half hours after the 
transfection, the media was removed and fresh media containing TNFα (200 U/ mL) or CPT 
(3 µM) was added. Twelve hours later the cells were lyzed. The luciferase activity was 
reported to µg protein and presented as a relative fold induction to the basal level measured in 
unstimulated cells. Error bars represent sample standard deviation. 
B) Same as in A except that the cells were transfected with increasing amounts of catalytically 
inactive MEKK1 (D1369A). 




Cells in 25 cm2 culture flasks in process of synchronization were transfected with 4 µg of the 
carrier vector (lanes 1 and 2) or the vector expressing dnMEKK1 (lane 3) or the vector 
expressing dnNIK (lane 4). Four hours after the release of the thymidine block and 24 hours 
after the transfection, CPT (10 µM) was added in the cell media. After 80 min incubation, 
cytoplasmic extracts were prepared in presence of phosphatase and protease inhibitors. 100 µg 
of proteins were immunoprecipitated with anti-IKKα antibody and the IKK kinase activity of 
the immunoprecipitated proteins tested on GST-IκBα.  
 
 
Fig. 7.   NF-κB inhibition increases cell killing by CPT. 
 
Different clones expressing either no exogenous HA-IκBα (filled diamond, dashed lines), low 
level HA-IκBα (open square), high level HA- IκBα (closed square), low level HA-IκBα 
(S32,36A) (open triangle), or high level HA-IκBα (S32,36) (closed triangle) were left 
untreated or were incubated for 48 hours with increasing concentrations of CPT (0.1-1 µM). 
Cell viability was estimated with WST1. Data points are means of three different experiments 
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